Osteosarcoma - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Osteosarcoma - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H1 2015', provides an overview of the Osteosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Osteosarcoma Overview 9
Therapeutics Development 10
Pipeline Products for Osteosarcoma - Overview 10
Pipeline Products for Osteosarcoma - Comparative Analysis 11
Osteosarcoma - Therapeutics under Development by Companies 12
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 13
Osteosarcoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Osteosarcoma - Products under Development by Companies 16
Osteosarcoma - Products under Investigation by Universities/Institutes 17
Osteosarcoma - Companies Involved in Therapeutics Development 18
Advaxis, Inc. 18
Amgen Inc. 19
Bayer AG 20
Bellicum Pharmaceuticals, Inc. 21
Eleison Pharmaceuticals, Inc. 22
Exelixis, Inc. 23
Isofol Medical AB 24
Merck & Co., Inc. 25
Merrimack Pharmaceuticals, Inc. 26
Neusentis 27
Novartis AG 28
Sutro Biopharma, Inc. 29
Osteosarcoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ADXS-HER2 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
alendronate sodium + HPMA + TNP-470 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AM-7209 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BL-1249 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
cabozantinib s-malate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Cell Therapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
celyvir - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
cisplatin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
everolimus - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
irinotecan sucrosofate liposomal - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ISOMC-091 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LLL-12 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MBC-11 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibody to Target GD2 for Osteosarcoma - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pazopanib hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pembrolizumab - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
radium Ra 223 dichloride - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Vaccine for Osteosarcoma - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Osteosarcoma - Recent Pipeline Updates 88
Osteosarcoma - Dormant Projects 130
Osteosarcoma - Discontinued Products 131
Osteosarcoma - Product Development Milestones 132
Featured News & Press Releases 132
Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting 132
Oct 30, 2014: Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study 132
May 27, 2014: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma 133
Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch 133
Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

List of Tables

Number of Products under Development for Osteosarcoma, H1 2015 10
Number of Products under Development for Osteosarcoma - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Osteosarcoma - Pipeline by Advaxis, Inc., H1 2015 18
Osteosarcoma - Pipeline by Amgen Inc., H1 2015 19
Osteosarcoma - Pipeline by Bayer AG, H1 2015 20
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 21
Osteosarcoma - Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 22
Osteosarcoma - Pipeline by Exelixis, Inc., H1 2015 23
Osteosarcoma - Pipeline by Isofol Medical AB, H1 2015 24
Osteosarcoma - Pipeline by Merck & Co., Inc., H1 2015 25
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 26
Osteosarcoma - Pipeline by Neusentis, H1 2015 27
Osteosarcoma - Pipeline by Novartis AG, H1 2015 28
Osteosarcoma - Pipeline by Sutro Biopharma, Inc., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Assessment by Combination Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Osteosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 88
Osteosarcoma - Dormant Projects, H1 2015 130
Osteosarcoma - Discontinued Products, H1 2015 131